Apellis Pharmaceuticals, Inc.

This study tested a drug called pegcetacoplan in 13 people whose rare kidney diseases (C3G or IC-MPGN) returned after a kidney transplant. The goal was to see if the drug could reduce signs of disease in the kidney and was safe. Participants received the drug or standard care, an…

This study tested the safety of a drug called pegcetacoplan given through a prefilled syringe for people with geographic atrophy, a form of age-related macular degeneration that causes vision loss. 44 adults aged 60 and older received the injection in one eye. The goal was to see…

This study looked at the long-term safety and effectiveness of a drug called pegcetacoplan in people with geographic atrophy, a late stage of dry age-related macular degeneration that causes vision loss. About 792 participants who had already been in earlier studies received the …

This study tested a drug called pegcetacoplan in 124 adults and teens with two rare kidney diseases (C3G and IC-MPGN). The goal was to see if the drug could reduce protein in the urine, a sign of kidney damage, compared to a placebo. Participants received injections twice a week …